Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Genetic Testing and Melanoma
Description
The discussion focused on the complexities and importance of genetic testing in melanoma, addressing both germline and somatic testing. Germline genetic testing seeks to identify hereditary predispositions to melanoma, with around 5-10% of melanoma cases being familial. Key indicators for hereditary risk include early onset of melanoma and multi-generational cases. The most well-known gene associated with melanoma risk is CDKN2A, which affects cell cycle regulation and increases the risk of melanoma and pancreatic tumors. The rule of threes is a guideline for when to consider genetic testing, emphasizing familial patterns of melanoma. Additionally, various other genes like CDK4, BRCA2, and MITF have associations with increased melanoma risk. Somatic testing, particularly for diagnostic purposes, utilizes gene expression profiling to differentiate between benign and malignant melanocytic lesions. Tests like the RNA-based diagnostic assay can aid in uncertain cases, although their accuracy can vary. Ultimately, recommendations for follow-up care include regular skin examinations and potential imaging for other cancer types based on genetic findings. The session underscored the evolving landscape of melanoma genetics and the significant role of genetic testing in patient management.
View moreConclusions
- Germline genetic testing in melanoma can identify heritable mutations like CDKN2A in familial clusters.
- Only about 5-10% of melanoma cases are familial, often influenced by shared genetics and environmental factors.
- Indicators such as early onset melanoma and multiple cancers suggest hereditary predisposition and warrant genetic testing.
- Mutations in genes like CDK4, BAP1, and BRCA2 are associated with increased melanoma risk.
- Gene expression profiling (GEP) can effectively differentiate between benign and malignant melanocytic lesions with high sensitivity and specificity.
- Clinical decisions regarding biopsy can be enhanced by using noninvasive testing methods, including the Pigmented Lesion Assay (PLA).
- Regular skin examinations and UV protection are recommended for patients with a genetic predisposition to melanoma.
- Somatic testing provides valuable information for diagnosis and treatment planning in suspected melanoma cases.
- Goldstein et al, J. Med Genet. 2007
- Swetter et al ., JAAD 2019
- Rossi et al ., 2019; Goldstein et al ., 2007
- Soura et al ., 2016a; Goldstein et al ., 1995; Toussi et al ., 2020; Helgadottir et al ., 2014; Borg et al ., 2000
- Potrony et al ., 2015; Harland et al ., 2016
- Aoude et al ., 2015a; Zhang et al ., 2014; Toussi et al ., 2020
- Harland et al ., 2016; Toussi et al ., 2020; Soura et al ., 2016b
- Leachman et al ., JAAD 2009
- Thomas P Potjer et al ., J. Med Genet 2018
- Gumaste et al ., BJD 2015
- Soura et al ., JAAD 2015
- Gerami et al ., JAMA Derm 2015
- Ciccarese et al ., J Transl Med 2020
- Shi et al, Nature Genetics 2014
- Robles-Espinoza et al ., Nature Genetics 2014
- Gerami et al ., JAAD 2016
- Ferris et al ., JAMA Derm 2017
- Clarke et al, Journal of Cutaneous Pathology 2015
- Boothby-Shoemaker et al ., Human Pathology 2023
- Ferris et al ., Derm Online J 2019
- Shah et al. JAAD Case Reports 2019